Description
Vatalanib is an inhibitor of VEGFR1/2/3. It decreases tumor growth in models of human glioma when administered with HET0016, a 20-HETE synthesis inhibitor.
Vatalanib
Product ID V024761
Cas No. 212141-54-3
Purity ≥98%
| Product Unit Size | Cost | Quantity | Stock |
|---|
Product Info
| Cas No. | 212141-54-3 |
|---|---|
| Purity | ≥98% |
| Formula | C20H15ClN4 |
| Formula Wt. | 346.82 |
| Chemical Name | Vatalanib |
| IUPAC Name | N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine |
| Synonym | PTK-787, PTK 787, PTK787, ZK-222584, ZK 222584, ZK222584, CGP-797870, ZK232934 |
| Solubility | Solubility in DMSO - ~100 mg/mL. |
Shipping and Storage
| Store Temp | -20°C |
|---|---|
| Ship Temp | Ambient |
Downloads
| MSDS | |
|---|---|
| Info Sheet |
References
Shankar A., Borin T., et al. Combination of vatalanib and a 20-HETE synthesis inhibitor results in decreased tumor growth in an animal model of human glioma. Onco Target Ther. 9:1204-19 (2016). PMID: 27022280.